Study: Estrogen-blocking drugs work for patients with breast cancer

08/18/2011 | EurekAlert!

PET imaging with 18F-fluoroestradiol showed that estrogen-receptor-blocking drugs such as tamoxifen and fulvestrant performed better than estrogen-eliminating drugs in stopping estrogen receptor in cancer cells of patients with breast cancer metastasis to the bones, according to a study published in Clinical Cancer Research. Tamoxifen also proved to be more effective than fulvestrant in hindering estrogen, according to the study. "Our findings support the ability of FES-PET to visualize the in vivo activity of endocrine therapy," the researchers said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL